SUBSCRIBE
SUBSCRIBE

Latus Bio

NEWS
NextGen
BioSpace’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
 · 
5 min read
 · 
Heather McKenzie
IN THE PRESS
Press Releases
Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO
June 2, 2025
 · 
3 min read
Press Releases
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy
May 20, 2025
 · 
3 min read
Press Releases
Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting
April 29, 2025
 · 
4 min read
Press Releases
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
February 24, 2025
 · 
3 min read
Pharm Country
Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing
May 2, 2024
 · 
7 min read
AWARDS
  • NextGen Class of 2025
JOBS